Based on the data from the MA. 17R trial, would you re-start an AI in post-menopausal women who stopped therapy after 5 years?

There is no single answer here. The MA17R trial raises the question but doesn't directly address it. That said, the risk is of recurrence is ongoing so readdressing the benefits of additional therapy is quite reasonable. Important considerations include duration of time off therapy, side effects exp...